Guys, I know we’re all in a bit of a celebratory mood after the two pieces of good news—the hiring of Dr. Annalisa Jenkins and the settlement between Northwest Biotherapeutics (NWBO) and Canaccord Genuity. If NWBO does receive cash from that settlement, it could reduce the need to issue as many new shares (and limit dilution) in the short term.
However, another 4,380,845 shares have been added to the total share count over the last two trading days.
I’m still hoping we get more positive news soon that can help stop the dilution and support the share price.
Monthly breakdown:
April 2026 (to date) 26,121,768 shares
(1,302,761 + 2,380,952 + 2,380,952 + 5,985,513 + 1,164,638 + 300,000+3,228,325+3,632,408+1,365,374 + 4,380,845)
(1,642,597,827 – 1,616,476,059)
March 2026: 17,732,625 shares
February 2026: 7,853,985 shares
January 2026: 22,808,837 shares
Total dilution (2026 YTD): 74,517,215 shares
Total shares outstanding: 1,642,597,827
AVG Dilution: 74,517,215 ÷ 87 business days= 856,520 shares per business day this year
Market Data 
Markets 
AI
